NSD2 drives triple-negative breast cancer progression via ATAD3A-dependent senescence.
Triple-negative breast cancer (TNBC) represents the most aggressive subtype of breast cancer, with limited therapeutic options and dismal prognosis. Histone methyltransferase NSD2 and its catalytic product H3K36me2 are established drivers of TNBC metastasis; however, the downstream effectors linking epigenetic regulati...